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In the era of communication technology, new options are now available for following-up patients implanted with pacemakers (PMs) and
deﬁbrillators (ICDs). Most major companies offer devices with wireless capabilities that communicate automatically with home transmitters,
which then relay data to the physician, thereby allowing remote patient follow-up and monitoring. These systems are being widely used in the
USA for remote follow-up, and have been more recently introduced in Europe, where their adoption is increasing. In this article, we describe
the currently existing systems, review the available evidence in the literature regarding remote follow-up and monitoring of PMs and ICDs,
and ﬁnally discuss some unresolved issues.
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Introduction
With increasing awareness of indications for pacemakers (PMs) and
especially implantable cardioverter deﬁbrillators (ICDs), the
number of patients with implantable devices has been growing
steadily. According to the recent ACC/AHA/HRS guidelines,
1
patients with a PM should be followed-up every 3–12 months,
and those with an ICD every 3–6 months (with more frequent
follow-ups as the battery approaches elective replacement,
Table 1). Altogether, this implies frequent visits for the patient,
and for the outpatient clinic a signiﬁcant increase in workload.
Transtelephonic monitoring has been available for many years,
but provides only basic information on battery status and
capture thresholds, and is limited to follow-up of PMs. More
recently, home transmitters are available from most major device
companies that are able to interrogate the device, either manually
by the patient using a telemetry wand or automatically using wire-
less technology. The data downloaded from the device by the
transmitter is then sent to the physician, using either the landline
phone or the GSM network. Many current PMs and ICDs are
able to automatically execute the tests that are performed manu-
ally at the outpatient clinic, such as battery status, lead impedances,
or sensing and capture thresholds. Data acquired automatically on
a pre-deﬁned periodic basis by the device can then be sent from
the patient’s home to the physician using the transmitter (thus
avoiding an unnecessary in-clinic visit), hence the term remote
follow-up. Another aspect is remote monitoring, which concerns
data acquired automatically on a daily basis by the device, with
unscheduled transmission of any pre-deﬁned alerts to the phys-
ician. These alerts may involve device integrity (e.g. battery
status, lead impedance), programming issues (e.g. disabling of ven-
tricular ﬁbrillation therapy, insufﬁcient safety margins for sensing or
capture), or medical data (e.g. arrhythmias, indication of lung ﬂuid
accumulation). Therefore, remote monitoring has the potential to
offer improved patient safety and quality of care. A comprehensive
review on remote monitoring and follow-up of implantable devices
has been published last year.
2 Our aim is to provide an update on
this rapidly evolving topic by presenting new data and describing
the currently available technology.
Existing remote monitoring
systems
Most major PM/ICD manufacturers have introduced their version
of remote monitoring system (Figure 1 and Table 2):
1. Home MonitoringTM (Biotronik, Berlin, Germany)
2. CareLink NetworkTM (Medtronic, Inc., MN, USA)
*Corresponding author. Tel: þ41 22 372 72 00, Fax: þ41 22 372 72 29, Email: haran.burri@hcuge.ch
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions&oxfordjournals.org
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doi:10.1093/europace/eup1103. Latitude Patient Management systemTM (Boston Scientiﬁc, St
Paul, USA)
4. Merlin.netTM (St Jude Medical, Sylmar, USA).
All current models of PMs and ICDs from these manufacturers
are able to be manually interrogated by the patient using a
telemetry wand incorporated in the home transmitter and are
thus able to perform remote follow-ups. However, automatic
wireless interrogation of the device is preferable, as it depends
less on patient compliance and allows frequent transmissions,
which is mandatory for effective remote monitoring. Automatic
wireless interrogation requires that the implanted device is
equipped with a micro-antenna for communication with the trans-
mitter located close to the patient. Data are then sent to a central
database using either the analogue landline phone system and a
toll-free number (Boston Scientiﬁc, Medtronic and St-Jude
Medical systems) or via the GSM network (Biotronik). The data
are processed and made accessible to the physician on a secured
webpage. The physician is informed by e-mail, SMS, fax, or
phone messages whenever critical data are available for consul-
tation. The types of events which trigger an alert can be custo-
mized for each patient. None of the systems currently allows
remote device programming (although this is technically feasible),
essentially for safety issues.
Biotronik (Home Monitoring
w)
This company is the pioneer in the ﬁeld of remote PM/ICD
follow-up and monitoring, with FDA approval of their ﬁrst
system in 2001. The transmitter (CardioMessenger
w) is a little
bigger than a cell phone and communicates wirelessly with the
................................................................................
Table 1 Minimum frequency of pacemakers/
implantable cardioverter deﬁbrillator/cardiac






Within 72 h of implantation X —
2–12 weeks post-implantation X —
Every 3–12 months (PM/CRT-P) X X
Every 3–6 months (ICD/CRT-D) X X
Annually until battery depletion X —
Every 1–3 months at signs of
battery depletion
XX
Adapted from Wilkoff et al.
1
Figure 1 Currently available transmitters from different device manufacturers.
H. Burri and D. Senouf 702implanted device within a radius of 2 m. It sends the retrieved data
to a centre in Germany using the GSM network, which is the main
advantage of the system. This is an important issue today, as the
patient may not have a landline phone connection (due to
increased use of cell phones) or may have a digital landline connec-
tion (currently incompatible with all device systems) or a DSL/
VOIP connection that requires special ﬁlters and converters. It
also means that the patient can be monitored continuously
around the clock, as the CardioMessenger has a rechargeable
battery that allows it to be carried around by the patient. Further-
more, the patient can continue to be monitored while travelling
abroad with the CardioMessenger, as the system is compatible
with most available GSM networks throughout the world.
Parameters for the alerts can be fully conﬁgured on the secured
webpage, without having to bring the patient into the clinic for a
manual transmission (Figure 2). EGMs of 30 s duration are sent
periodically that may assist with data interpretation (Figure 3).
Biotronik is the only company today that offers PMs with wireless
technology for remote monitoring (other manufacturers are also
going to offer wireless PMs in the future).
Medtronic (Carelink NetworkTM)
The system has been introduced in Europe in a pilot study in
2005.
3 The ICD communicates with a wireless transmitter
(Home Monitor) within a radius of 3 m, which is usually placed
in proximity to the patient’s bed. Data are sent via an analogue
phone landline, which can only be used in the patient’s country
of residence (a carrier-independent, international solution is
being developed). Pre-scheduled remote follow-up transmissions
(that take place at 03:00) may be programmed remotely, but can
be executed only after 21 days. In addition, for remote monitoring
purposes, detection of an event (e.g. abnormal lead impedance
etc.) will immediately trigger the ICD to attempt communication
with the Home Monitor (with repeated attempts every 3 h
during 3 days in case of inability to establish communication, and
then by audible alerts). The parameters for remote monitoring
can be conﬁgured individually in each patient, with pre-deﬁned
degrees of urgency (‘red’ and ‘yellow’ alerts, Figure 2), which
helps with data triage. However, the threshold settings for each
alert require in-clinic programming of the device. An advantage
with the latest generation of Medtronic implantable devices is
the ability to automatically perform a wide range of tests, including
automatic atrial, right ventricular, and left ventricular capture
thresholds, which facilitates full remote follow-up. A unique
feature with Medtronic dual-chamber and biventricular ICDs is
the Optivolw algorithm that monitors transthoracic impedance
for detecting lung ﬂuid accumulation, which may be potentially
useful for remote monitoring of patients with heart failure.
...............................................................................................................................................................................
Table 2 Comparison of different remote monitoring systems
Biotronik Home
MonitoringTM





Radiofrequency Radiofrequency Radiofrequency Radiofrequency
Data transmission GSM network Analogue phoneline Analogue phoneline Analogue phoneline
Transmitter Mobile Stationary Stationary Stationary
Frequency of
transmissions
Daily FU; Alert events Scheduled FU; Alert events Scheduled FU; Alert events Scheduled FU; Alert events
Remote follow-up Yes Yes Yes Yes
Remote monitoring Yes Yes Yes Yes
Physician notiﬁcation SMS, e-mail, fax SMS, e-mail Fax, phone Fax, e-mail, SMS
Feedback to patient via
transmitter
LED indicating normal status
or call to clinic
LED indicating normal status
or call to clinic
Automatic text and audio
messages




30 s (monthly periodic
EGMs)
10 s 10 s 30 s
IEGM (arrhythmic
episodes)
All memorized episodes All memorized episodes All memorized episodes All memorized episodes
Special features Alerts fully conﬁgurable
online




scales and BP cuffs
Alerts fully conﬁgurable online
Automatic RV and LV
thresholds (only Lumax
500/540)





Possibility of sending automated
phone calls to patients
Wireless PMs Conﬁgurable red and yellow
alerts
Conﬁgurable red and yellow
alerts
Automatic RA, RV, and LV pacing




RA, Right atrial; RV, right ventricular; LV, left ventricular; IEGM, intracardiac electrogram; BP, blood pressure.
Remote monitoring and follow-up of PMs and ICDs 703Figure 2 Remote monitoring parameters (print screens) for CRT-D devices available at the University Hospital of Geneva at the time this
manuscript was submitted. The Biotronik Lumax-540 CRT-D (left) can be fully conﬁgured online. Parameters of a Medtronic Consulta CRT-D
(right) can be deﬁned as red or yellow alerts (or website alert only) that trigger different urgencies of notiﬁcation.
Figure 3 (A) Biotronik Home Monitor showing trends of AS–VS events (black dots) and As–Vp events (blue diamonds). Alerts of reduced
(, 85%) CRT delivery are indicated (‘CRT low’ arrows) and coincide with increased percentage of AS–VS events (black dots). This would
suggest that the AV interval is programmed too long. (B) The real-time EGM strip available by remote monitoring however shows that the
AS–VS events are due to premature atrial beats (red asterisks) with a short intrinsic AV interval (most probably due to proximity of the
ectopic focus with the AV node). Doses of beta-blockers were increased, with improvement in CRT delivery.
H. Burri and D. Senouf 704Boston Scientiﬁc (Latitude Patient
Management systemTM)
This system is to be introduced in Europe in 2009. The transmitter
also uses an analogue landline for data transmission, which may be
conﬁgured for use in various countries (but may require plug
adapters). A unique feature of the system is the possibility to
connect wireless weight scales and blood pressure cuffs for
remote monitoring of heart failure status (Figure 1). Also, the
patient can self-report heart failure symptoms into the system
on a weekly basis (such as fatigue, ankle swelling, orthopnea
etc.). Event notiﬁcations can be conﬁgured individually in each
patient based upon ‘red’ and ‘yellow’ alerts. Furthermore, the
system allows customizable data transmission to different phys-
icians (for example to the general practitioner or general cardiol-
ogist in addition to the heart rhythm specialist), which improves
networking of heart failure management.
St Jude Medical (Merlin.netTM)
The wireless transmitter (Merlin@home) has been introduced in
Europe in 2008 at pilot centres. The system communicates auto-
matically by radiofrequency with the implantable device and
sends data to the physician using the analogue landline system (a
cellular adapter card is planned for 2009). As with the other avail-
able systems, remote monitoring is possible with alerts being sent
by e-mail, fax, or SMS to notify the physician of events. A useful
feature is the ability for the physician to indicate alerts or remin-
ders of scheduled in-ofﬁce visits on the patient’s transmitter, and
to send automated phone calls to patients indicating the results
of the remote follow-up (e.g. that everything is normal). The
next generation of ICDs will also have capture thresholds for all
leads, which will facilitate full remote follow-up.
Potential beneﬁts and existing
evidence of utility
Reduction of in-clinic visits
In a study by Brugada,
4 271 patients with a Biotronik ICD and
Home Monitoringw system were followed for 12 months with
routine follow-up every 3 months. Retrospective analysis of the
Biotronik Home Monitoringw data showed that as many as half
of the regular scheduled visits may have been skipped, without
impairing patient safety.
More recently Heidbuchel et al.
5 retrospectively analysed data
from 1739 in-clinic ICD visits in 169 patients. The authors found
that only 6% of scheduled in-clinic visits resulted in device repro-
gramming or patient hospitalization. Thus, in 94% of all scheduled
visits, remote follow-up would have sufﬁced. Furthermore, they
estimated that ICD remote monitoring could potentially diagnose
. 99% of arrhythmia- or device-related problems, if combined
with clinical follow-up by the local general practitioner and/or
the referring cardiologist.
Preliminary results of the TRUST (Lumax-T/Lumos-T safely
RedUceS rouTine ofﬁce device follow-up) study were recently
presented.
6 Data on 1312 patients with a Biotronik VR/DR ICD
were randomized to standard (3 months) in-ofﬁce visits vs.
remote monitoring (with in-ofﬁce visits at 3 and 15 months).
Remote monitoring and follow-up resulted in a 43% relative
reduction in visits (from 3.0 to 2.5 visits/patient-year, P , 0.001)
with a better adherence to the scheduled follow-up timetable.
The trial demonstrated also similar safety (death, stroke, or
event-related surgery) by remote monitoring compared with
in-clinic control group.
In addition to reducing scheduled in-clinic visits, remote
follow-up may avoid unscheduled visits following an ICD
shock.
7,8 After such an event, the patient may perform manual
interrogation to upload data to the physician for determining if
the shock was appropriate or not, and it may then be decided
whether the patient should be seen for device reprogramming
or modiﬁcation of drug therapy.
Patients with cardiac resynchronization therapy (CRT) may
require special consideration, as they are usually sicker and have
more complex devices with speciﬁc issues (e.g. requirement for
atrio-ventricular interval optimization, greater variations in left ven-
tricular thresholds, phrenic nerve capture etc.). Thus frequency of
follow-up and requirement for in-ofﬁce device reprogramming may
be greater than in patients with standard PMs or ICDs. In a report
from the Insync ICD Italian Registry,
9 there was a marked
reduction in number of interrogations requiring reprogramming
between the ﬁrst 6 months of follow-up and subsequent
periods, as pacing and CRT delivery parameters were usually opti-
mized relatively quickly after implantation and maintained unmodi-
ﬁed thereafter. This means that remote follow-up is an acceptable
alternative in these patients, especially with the advent of algor-
ithms that automatically adjust device settings such as left ventricu-
lar pacing output based upon daily threshold measurements.
10
Even though remote device monitoring and interrogation has
the potential to reduce numbers of in-clinic visits, it does not
entirely replace direct contact (that is valued by many patients).
According to current guidelines, in-ofﬁce visits need to take
place at least yearly (Table 1), but this may change in the future
for subsets of patients (e.g. primary prevention ICD patients
without clinical events or elderly/disabled patients etc.).
Improved patient safety
Figure 4 shows an example of a patient in whom remote follow-up
proved to be life-saving.
In a recent study by Nielsen et al.,
11 patients with a Biotronik
ICD and Home MonitoringTM system were prospectively enrolled
in a registry for a mean follow-up of 10 months. At least one Home
Monitoring event occurred in 41% of patients, consisting mostly of
clinical events (such as arrhythmias). Technical events (inappropri-
ate shock, lead impedance issues etc.) occurred in 3% of patients.
The temporal distribution of home monitoring events is interest-
ing, as over 60% occurred during the ﬁrst month following the
last visit. In another report using the Biotronik Home Monitoring
system with over 3 million transmissions in . 11 000 patients,
12
the mean interval between last follow-up and occurrence of
events notiﬁed by home monitoring was 26 days. This represented
a temporal gain of 154 days for event notiﬁcation in patients usually
followed at 6 months intervals and of 64 days in patients usually fol-
lowed at 3 months intervals. This has implications for diagnosing
technical issues such as lead fracture, device malfunction,
13 or




15 minlater, the patientcollapsed due to rapid incessantventriculartachycardia (VT) that led to22 ICDshocks. Injection ofamiodarone resulted in
slowing and ﬁnally disappearance of the VT. The patient developed multiorgan failure, but recovered subsequently and was seen in-ofﬁce 1 month
later, with no events. (C) Print screen of the CareLink website of remote interrogation of the device 6 months after the arrhythmic storm (asterisk)
showing no arrhythmia (faster than 113 b.p.m.), with improvement of the patients’ physical activity (arrow).
H. Burri and D. Senouf 706clinical events such as onset of atrial ﬁbrillation (AF). Continuous
monitoring for AF is particularly interesting, as it offers new treat-
ment strategies for anti-arrhythmic drug therapy and anticoagula-
tion. In a report by Ricci et al.
14 of 166 patients implanted with a
Biotronik PM or ICD using the Home Monitor system during a
mean follow-up of 16 months, remote monitoring alerts for AF
were triggered in 25% of patients, with an unscheduled follow-up
(in-ofﬁce or by phone) resulting in interventions involving anti-
arrhythmic drug therapy, anticoagulation, or antiplatelet drug
initiation, external cardioversion, or device reprogramming, in 17%
of all patients.
Remote monitoring may be particularly useful in patients with
CRT, as they are most likely to have transmissions of medically
related events.
12 A number of different randomized trials are cur-
rently underway to assess the utility of monitoring lung ﬂuid over-
load in patients with heart failure (Table 3).
Failure of ICD leads is a major issue and has been highlighted by
the Fidelis lead recall. The Medtronic lead integrity alert algorithm
has been shown to give a warning of impending inappropriate
shocks by at least 3 days advance in 76% of patients,
15 and triggers
an audible alert that may prompt the patient to seek attention.
However, these audible alerts may not be heard by the patient
in time, resulting in inappropriate shocks.
16,17 Detection of lead
failure may therefore be enhanced by remote monitoring. In a
report of 54 patients with an ICD lead failure, remote monitoring
by the Biotronik Home Monitoring system resulted in a signiﬁcant
reduction in the incidence of inappropriate shocks and sympto-
matic pacing inhibition compared with those without remote
monitoring (27.3 vs. 53.4%, P ¼ 0.04).
18 Inappropriate shocks
occur for a variety of reasons other than lead dysfunction. In a
recent report on 35 patients with Brugada syndrome implanted
with a Biotronik ICD followed by Home Monitoring,
19 identiﬁ-
cation of problems by remote monitoring such as T-wave oversen-
sing, external electromagnetic interference and sinus tachycardia
led to device reprogramming that may have prevented shocks.
Remote follow-up and monitoring can also be used for tracking
product performance in a large number of patients, and may allow
earlier identiﬁcation of issues with speciﬁc models. The large
amount of data gathered in a consistent manner also has the
potential to facilitate medical research.
Increased patient satisfaction
The ﬁrst studies evaluating patient satisfaction by remote follow-up
of ICDs were published in 2004 using the Medtronic Carelink
system
20 and the St Jude Medical HouseCall IITM.
21 Patient satisfac-
tion with the systems was high in both studies. In an Italian study,
67 patients implanted with a Medtronic CRT-D were followed
remotely using the CareLinkTM system.
8,22 Remote follow-ups
were preferred to in-clinic visits by 78% of the patients. Satisfaction
by the physicians was also very favourable. Likewise, in another
study using the Medtronic CareLinkTM conducted in Finland,
23
the patients’ and physicians’ level of satisfaction with the system
was high. Our own experience is that most patients readily
accept remote monitoring, and feel secured by the use of this tech-
nology to improve their healthcare.
Potential cost savings
There are a few studies that assess the potential cost/beneﬁt of
remote monitoring-assisted care compared with conventional
follow-up, and all are based on the fact that remote data access
may decrease the rate of inhospital patient visits. Using a French
database of 502 ICD-patients followed in tertiary care hospitals,
...............................................................................................................................................................................
Table 3 Ongoing multicentre randomized studies on remote device monitoring and follow-up registered on
www.clinicaltrials.gov
Study Sponsor Device Projected
size
Primary outcome measures Status
CONNECT
28,29 Medtronic CRT-D, ICD-DR 2000 Reduction in time to clinical decision for arrhythmias,




30 Biotronik CRT-D 300 Mortality and morbidity in patients with AF Recruiting
EuroEco




ICD-VR, ICD-DR 1600 Safety and cost-effectiveness Recruiting
HomeCARE II
33 Biotronik CRT-D, ICD-VR,
ICD-DR




34 Biotronik CRT-D, ICD-DR 2718 Thromboembolic events and bleeding in patients with AF
managed by pre-deﬁned anticoagulation plan.
Recruiting
IN-TIME
35 Biotronik CRT-D, ICD-VR,
ICD-DR
620 Mortality, hospitalization for heart failure, clinical status Recruiting
OptiLink-HF
36 Medtronic CRT-D, ICD-VR,
ICD-DR




37 Biotronik ICD-VR, ICD-DR 150 Psychosomatic evaluation Recruiting
TRUST
6,38 Biotronik ICD-VR, ICD-DR 1516 Number of ICD follow-ups and safety Active, not
recruiting
Data were retrieved on 22 February 2009.




is noteworthy that this study did not include reimbursement for the
time spent reviewing remote monitoring data.
Recently, an interesting Finnish study
23 replaced standard ICD
follow-up at 3 and 6 months after implantation, by remote data
transmission using the Medtronic CareLinkTM system. This was
safe, reduced time burden for patient and inhospital staff, and
was also cost-effective. However, one should note that the econ-
omic impact of remote follow-up may not be the same in all
countries, due to the fact that indirect costs (such as travel
expenses and sickness allowance) played a major role.
Speciﬁc issues
Optimal workﬂow
Even though reports suggest that the physician is unlikely to be
submerged by incoming data from his patients (for example, the
mean numbers of events per patient per month reported in the
largest study to date
12 was only 0.6), this will probably depend
to a large extent on programming of the alerts and data triage.
Ricci et al.
25 have described a system whereby a specialized
nurse connects to the home monitoring website for checking
data from all their 117 patients at least every 15 days and whenever
an event report was received. Only 6% of events were then
relayed to the physician for further evaluation. This workﬂow
resulted in a mean of 59 min/week for the nurse and 12 min/
week for the physician to analyse home monitoring data. A well-
organized clinic will also ensure that alerts are responded to in a
timely manner.
Several companies are working on compatibility of their systems
with electronic medical records for exporting remote follow-up
data. This will considerably alleviate the clinic’s workload and
help streamline workﬂow.
Legal aspects
The patient needs to be informed of the purpose and limitations of
remote monitoring, such as the fact that it does not replace an
emergency service or absence of dealing with alert events
outside ofﬁce hours. Before initiating remote monitoring and
follow-up, the patient may be requested to sign a written informed
consent stating these points and authorizing transmission of per-
sonal data to third parties, respect of privacy, and conﬁdentiality
of patient data by device companies should be subjected to
strict rules, described in contracts.
Patient privacy and security
In order to test the vulnerability of security breaches by hackers
accessing devices with wireless capability, Halperin et al.
26 per-
formed laboratory tests on a Medtronic Maximo DR ICD. After
having partially reversed the ICD’s communications protocol
with an oscilloscope and a software radio, they performed
several software radio-based attacks that were able to retrieve
uncrypted personal patient data, as well as change device settings
(including commanded shocks). This report triggered considerable
media coverage, although it is believed that the risk of unauthor-
ized access to an ICD is unlikely, given the considerable technical
expertise required.
27 There have been no reports to date of
hacking of implantable devices. Another consideration, however,
is hacking of the internet server database.
Reimbursement
In the USA, Medicare and Medicaid have expanded reimbursement
for remote device monitoring for all states since 2006. Reimburse-
ment rates vary from state to state, and in some instances are the
same as an in-ofﬁce visit without device programming. In the UK,
Germany, and Portugal, reimbursement for remote monitoring is
similar to that offered for standard follow-up visits.
Conclusions
Remote monitoring and follow-up are likely to become the stan-
dard of care for patients with PMs and ICDs, as they have the
potential to improve patient safety and satisfaction, to support efﬁ-
cient use of resources, and to reduce costs. Existing data show that
current technology for remote monitoring is reliable and that it is
readily accepted by patients and their physicians. Large randomized
trials are underway that will hopefully prove that remote monitor-
ing improves patient outcome. Speciﬁc issues such as reimburse-
ment need to be dealt with by the authorities, in order to
ensure that this solution is a viable one.
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